博瑞醫藥(688166.SH):博瑞製藥通過藥品GMP符合性檢查
格隆匯8月10日丨博瑞醫藥(688166.SH)公佈,近日,公司全資子公司博瑞製藥(蘇州)有限公司(“博瑞製藥”)從江蘇省藥品監督管理局網站獲悉《藥品GMP符合性檢查結果公吿(2021第60號)》。
此次博瑞製藥通過藥品GMP符合性檢查,涉及磷酸奧司他韋原料藥、硬膠囊劑生產線,表明上述原料藥、製劑產品生產線符合中華人民共和國《藥品生產質量管理規範》要求,標誌着博瑞製藥位於泰興經濟開發區濱江南路22號及蘇州工業園區星湖街218號C25樓、C26樓、C28樓的生產基地可以正式生產和銷售磷酸奧司他韋原料藥和磷酸奧司他韋膠囊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.